The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10692 malaria professionals are enjoying the free benefits of MalariaWorld today

vivax

Has COVID19 derailed Bhutan’s national malaria elimination goal? A commentary

January 9, 2021 - 13:49 -- Open Access
Author(s): 
Kinley Penjor, Tobgyal, Tandin Zangpo, Archie C. A. Clements, Darren J. Gray and Kinley Wangdi
Reference: 
Malaria Journal 2021 20:20, 6 January 2021

The COVID-19 pandemic has resulted in massive global disruptions with considerable impact on the delivery of health services and national health programmes. Since the detection of the first COVID-19 case on 5th March 2020, the Royal Government of Bhutan implemented a number of containment measures including border closure and national lockdowns.

Clinical spectrum and predictors of severe Plasmodium vivax infections at a tertiary care center in North India

January 6, 2021 - 13:15 -- Open Access
Author(s): 
Walia D, Arora U, Baitha U, Kumar A, Ranjan P, Soneja M, Verma N, Khan MA, Aggarwal P, Biswas A, Wig N
Reference: 
Drug Discov Ther. 2020 Dec 31

Traditionally attributed only to Plasmodium falciparum, Plasmodium vivax has recently been reported to cause a significant burden of complicated malaria cases. The present study aimed to delineate the clinical spectrum and identify predictors for severe disease. This was a prospective observational cohort study conducted at a tertiary care hospital in North India. Patients with acute febrile illness (AFI) aged at least 14 years were included if they were diagnosed with vivax malaria based on rapid kits or peripheral smears.

Tafenoquine: a toxicity overview

December 16, 2020 - 10:21 -- Open Access
Author(s): 
Chu CS, Hwang J
Reference: 
Expert Opin Drug Saf. 2020 Dec 11

A century long history in 8-aminoquinolines, the only anti-malaria drug class preventing malaria relapse, has resulted in the approval of tafenoquine by the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) and to date registration in Brazil and Thailand. Tafenoquine is an alternative anti-relapse treatment for vivax malaria and malaria prophylaxis. It should not be given in pregnancy, during lactation of infants with glucose-6-phosphate dehydrogenase (G6PD) unknown or deficient status, and in those with G6PD deficiency or psychiatric illness.

Misidentification of Plasmodium ovale as Plasmodium vivax malaria by a microscopic method: a meta-analysis of confirmed P. ovale cases

December 16, 2020 - 10:17 -- Open Access
Author(s): 
Kotepui M, Masangkay FR, Kotepui KU, De Jesus Milanez G
Reference: 
Sci Rep. 2020 Dec 11;10(1):21807

Plasmodium ovale is a benign tertian malaria parasite that morphologically resembles Plasmodium vivax. P. ovale also shares similar tertian periodicity and can cause relapse in patients without a radical cure, making it easily misidentified as P. vivax in routine diagnosis. Therefore, its prevalence might be underreported worldwide. The present study aimed to quantify the prevalence of P. ovale misidentified as P. vivax malaria using data from studies reporting confirmed P. ovale cases by molecular methods. Studies reporting the misidentification of P. ovale as P.

Decreasing trend of imported malaria cases but increasing influx of mixed P. falciparum and P. vivax infections in malaria-free Kuwait

December 16, 2020 - 10:12 -- Open Access
Author(s): 
Iqbal J, Al-Awadhi M, Ahmad S
Reference: 
PLoS One. 2020 Dec 11;15(12):e0243617

Malaria still continues to be the most important parasitic disease worldwide, affecting 228 million people and causing 405,000 deaths each year. In this retrospective study during 2013 to 2018, we documented the incidence of imported malaria infection and evaluated the impact of malaria preventive measures in Kuwait, a non-endemic country. The epidemiologic and demographic data of all malaria cases was collected from the Infectious Diseases Hospital, Kuwait where all suspected cases of malaria are referred for confirmation and therapeutic intervention.

Monitoring insecticide resistance in malaria vectors in Shandong Province: approaching malaria elimination

December 3, 2020 - 13:27 -- Open Access
Author(s): 
Cheng P, Liu L, Lv Y, Wang H, Gong M, Liu H
Reference: 
J Vector Ecol. 2020 Dec;45(2):380-383

Since the malaria elimination program was launched in China in 2010, the number of local infections has declined from 4,262 in 2010 to none in 2017, indicating remarkable achievements for prevention and treatment (Zhang et al. 2018). Shandong Province is a malaria‐endemic area, and vivax malaria is prevalent throughout the province.

Genomic surveillance of Plasmodium falciparum and Plasmodium vivax cases at the University Hospital in Tegucigalpa, Honduras

December 3, 2020 - 12:36 -- Open Access
Author(s): 
Valdivia HO, Villena FE, Lizewski SE, Garcia J, Alger J, Bishop DK
Reference: 
Sci Rep. 2020 Dec 1;10(1):20975

Malaria continues to be an important health problem in Honduras despite major progress achieved reducing its incidence in the last two decades. In a context of case reduction, continuing surveillance of parasite diversity and drug resistance is an important component to assist effective malaria control strategies and support risk assessments. In this study, we employed next generation sequencing on collected Plasmodium vivax and P. falciparum samples from the Hospital Escuela (University Hospital) in Honduras between 2005 and 2017.

NOT Open Access | Household prevalence of P. falciparum, P. vivax, and P. ovale in the Democratic Republic of the Congo, 2013-2014

December 3, 2020 - 12:31 -- NOT Open Access
Author(s): 
Mitchell CL, Topazian HM, Brazeau NF, Deutsch-Feldman M, Muwonga J, Sompwe E, Tshefu AK, Mwandagalirwa MK, Parr JB, Juliano JJ
Reference: 
Clin Infect Dis. 2020 Nov 26:ciaa1772

In a cross-sectional molecular study in the Democratic Republic of Congo, 78% of households had at least one member infected with Plasmodium falciparum, vivax, and/or ovale spp. 47% of children and 33% of adults tested positive for at least one species.

Not Open Access | Hypnozoites in Plasmodium: Do Parasites Parallel Plants

December 2, 2020 - 08:30 -- NOT Open Access
Author(s): 
Merrick CJ
Reference: 
Trends Parasitol. 2020 Nov 27:S1471-4922(20)30299-3

The phenomenon of relapsing malaria has been recognised for centuries. It is caused in humans by the parasite species Plasmodium vivax and Plasmodium ovale, which can arrest growth at an early, asymptomatic stage as hypnozoites inside liver cells. These dormant parasites can remain quiescent for months or years, then reactivate causing symptomatic malaria.

Characterisation of plasmodial transketolases and identification of potential inhibitors: an in silico study

December 2, 2020 - 08:00 -- Open Access
Author(s): 
Rita Afriyie Boateng, Özlem Tastan Bishop and Thommas Mutemi Musyoka
Reference: 
Malaria Journal 2020 19:442, 30 November 2020

Plasmodial transketolase (PTKT) enzyme is one of the novel pharmacological targets being explored as potential anti-malarial drug target due to its functional role and low sequence identity to the human enzyme. Despite this, features contributing to such have not been exploited for anti-malarial drug design. Additionally, there are no anti-malarial drugs targeting PTKTs whereas the broad activity of these inhibitors against PTKTs from other Plasmodium spp. is yet to be reported. This study characterises different PTKTs [Plasmodium falciparum (PfTKT), Plasmodium vivax (PvTKT), Plasmodium ovale (PoTKT), Plasmodium malariae (PmTKT) and Plasmodium knowlesi (PkTKT) and the human homolog (HsTKT)] to identify key sequence and structural based differences as well as the identification of selective potential inhibitors against PTKTs.

Pages

Subscribe to RSS - vivax